A focus on LBCL patients in partial remission in the CAR-T era

The treatment paradigm for large B-cell lymphoma (LBCL) has undergone significant changes in recent years. Patients who fail to achieve a complete response (CR) after first-line therapy (1L) or relapse within 12 months are considered to have a poor prognosis. For these individuals, new therapeutic o...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Giuseppe Tarantini, Elena Arcuti, Caterina Buquicchio, Vera Carluccio, Gaetano De Santis, Candida Rosaria Germano, Mariangela Leo, Daria Carmela Loconte, Sonia Mallano, Rosanna Maria Miccolis, Teresa Maria Santeramo, Vanda Strafella, Vincenzo Pavone
Format:	Artigo
Sprog:	Inglês
Udgivet:	Frontiers Media S.A. 2025-11-01
Serier:	Frontiers in Hematology
Fag:	DLBCL partial response (PR) CAR-T bispecific antibody autologous stem cell transplantation (ASCT)
Online adgang:	https://www.frontiersin.org/articles/10.3389/frhem.2025.1675099/full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!